Publications by authors named "Michiko Inukai"
Article Synopsis
- - This study focused on 111 patients with advanced gastric cancer who were treated with nivolumab to monitor their disease progression and evaluate treatment response using serum inflammatory markers like CRP-to-albumin ratio (CAR), platelet-to-lymphocyte ratio (PLR), and neutrophil-to-lymphocyte ratio (NLR).
- - Results indicated an overall response rate of 11.7% and a disease control rate of 44.1%, with median overall survival of 14 months and progression-free survival of 4.1 months.
- - Changes in the inflammatory markers after therapy proved to be useful in predicting treatment response, with specific cutoff values identified for CAR, PLR, and NLR that correlated
A case study of pyloric stenosis caused by metastatic lobular carcinoma of breast.
J Surg Case Rep
December 2023
Metastasis to the gastrointestinal tract is rare. A 59-year-old woman who had a history of an invasive lobular carcinoma of breast with clinical complete response visited our hospital and complained of an upper abdominal pain and distension. We performed an upper gastrointestinal endoscopy which showed only a gastric ulcer without any malignant findings.
View Article and Find Full Text PDFSurface CD3-negative monomorphic epitheliotropic intestinal T-cell lymphoma.
J Clin Exp Hematop
September 2022
Intestinal T/NK-cell lymphomas include enteropathy-associated T-cell lymphoma (EATL), monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL), indolent T-cell lymphoproliferative disorders of the GI tract (ITCLPD), extranodal NK/T-cell lymphoma, nasal type (ENKTL), and intestinal T-cell lymphoma NOS (ITCL-NOS). Here we describe a case of surface CD3-negative MEITL. A 63-year-old Japanese female had a tumor located in the conglomerated ileum, which formed multiple mass lesions.
View Article and Find Full Text PDFArticle Synopsis
- * Preoperative treatment with imatinib led to a significant reduction in tumor size (44%) after just two weeks, and the suspected invasion was no longer evident six months later.
- * Following successful laparoscopic resection of the tumor and an uneventful recovery, the patient has been alive for 8 months post-surgery without any signs of tumor recurrence, highlighting the effectiveness of preoperative imatinib therapy for large GISTs.
Donor quality of life in living-donor lobar lung transplantation.
J Heart Lung Transplant
December 2011
Background: Living-donor lobar lung transplantation has been established as a life-saving option for end-stage pulmonary diseases. However, factors associated with quality of life (QOL) of living lung donors have not been fully investigated.
Methods: A cross-sectional study was performed at Okayama University using the version 2 questionnaire of the 36-item Short Form (SF-36) Health Survey.